Evidence map›Paper›PMID 34633332›Full record

ArticleJournal of Parkinson's disease2022

Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease.

Cloé Domenighetti, Pierre-Emmanuel Sugier, Ashwin Ashok Kumar Sreelatha, Claudia Schulte, Sandeep Grover, Océane Mohamed, Berta Portugal, Patrick May, Dheeraj R Bobbili, Milena Radivojkov-Blagojevic and 70 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers.Movement disorders : official journal of the Movement Disorder Society · 2023
    Pooled it
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

80 authors.

Cloé DomenighettiUniversité Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
Pierre-Emmanuel SugierUniversité Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
Ashwin Ashok Kumar SreelathaCentre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.
Claudia SchulteDepartment for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.
Sandeep GroverCentre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.
Océane MohamedUniversité Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
Berta PortugalUniversité Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
Patrick MayTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.
Dheeraj R BobbiliTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.
Milena Radivojkov-BlagojevicInstitute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.
Peter LichtnerInstitute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.
Andrew B SingletonMolecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.
Dena G HernandezMolecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.
Connor EdsallMolecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.
George D MellickGriffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia.
Alexander ZimprichDepartment of Neurology, Medical University of Vienna, Austria.
Walter PirkerDepartment of Neurology, Wilhelminenspital, Austria.
Ekaterina RogaevaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Anthony E LangEdmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.
Sulev KoksCentre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
Pille TabaDepartment of Neurology and Neurosurgery, University of Tartu, Estonia.
Suzanne LesageSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.
Alexis BriceSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.
Jean-Christophe CorvolSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.
Marie-Christine Chartier-HarlinUniv. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog- Centre de Recherche Lille Neurosciences & Cognition, Lille, France.
Eugénie MutezUniv. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog- Centre de Recherche Lille Neurosciences & Cognition, Lille, France.
Kathrin BrockmannDepartment for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.
Angela B DeutschländerDepartment of Neurology, Ludwig Maximilians University of Munich, Germany.
Georges M HadjigeorgiouDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece.
Efthimos DardiotisDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece.
Leonidas Stefanis1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Athina Maria Simitsi1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Enza Maria ValenteDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Simona PetrucciUOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy.
Stefano DugaDepartment of Biomedical Sciences - Humanitas University, Milan, Italy.
Letizia StranieroDepartment of Biomedical Sciences - Humanitas University, Milan, Italy.
Anna ZecchinelliParkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italy.
Gianni PezzoliParkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italy.
Laura BrighinaDepartment of Neurology, San Gerardo Hospital, Monza, Italy.
Carlo FerrareseDepartment of Neurology, San Gerardo Hospital, Monza, Italy.
Grazia AnnesiInstitute for Biomedical Research and Innovation, National Research Council, Cosenza, Italy.
Andrea QuattroneInstitute of Neurology, Magna Graecia University, Catanzaro, Italy.
Monica GagliardiInstitute of Molecular Bioimaging and Physiology National Research Council, Catanzaro, Italy.
Hirotaka MatsuoDepartment of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan.
Yusuke KawamuraDepartment of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan.
Nobutaka HattoriDepartment of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.
Kenya NishiokaDepartment of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.
Sun Ju ChungDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Yun Joong KimDepartment of Neurology, Yonsei University College of Medicine, Seoul, South Korea.
Pierre KolberNeurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
Bart Pc van de WarrenburgRadboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.
Bastiaan R BloemRadboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.
Jan AaslyDepartment of Neurology, St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway.
Mathias ToftDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Lasse PihlstrømDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Leonor Correia GuedesInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Joaquim J FerreiraInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Soraya BardienDivision of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa.
Jonathan CarrDivision of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa.
Eduardo TolosaParkinson's disease & Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Mario EzquerraLab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Catalonia.
Pau PastorFundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain.
Monica Diez-FairenFundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain.
Karin WirdefeldtDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Nancy L PedersenDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Caroline RanDepartment of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Andrea C BelinDepartment of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Andreas PuschmannLund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden.
Clara HellbergLund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden.
Carl E ClarkeUniversity of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, UK.
Karen E MorrisonFaculty of Medicine, Health and Life Sciences, Queens University, Belfast, UK.
Manuela TanDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Dimitri KraincDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Lena F BurbullaDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Matt J FarrerDepartment of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Rejko KrügerTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.
Thomas GasserDepartment for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.
Manu SharmaCentre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.
Alexis ElbazUniversité Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
Comprehensive Unbiaised Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease (Courage-PD) consortium

Funding

Genome wide SNP analysis in Parkinson's diseaseZ01AG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2006 to 2008
$2.6M
MIDCAREER AWARD IN PATIENT ORIENTED RESEARCH ON AGINGK24AG000949 · NIA · YALE UNIVERSITY · PI INOUYE, SHARON K. · 1999 to 2009
$1.4M
Environmental Factors for Parkinson's in Swedish TwinsR01ES010758 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PEDERSEN, NANCY L · 2001 to 2004
$1.4M
DEMENTIA IN TWINSR01AG008724 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GATZ, MARGARET · 1990 to 2002
$1.4M
Intramural NIH HHS Z01 AG000949Intramural NIH HHS Z99 AG999999Medical Research CouncilNIA NIH HHS K24 AG000949NIA NIH HHS R01 AG008724NIEHS NIH HHS R01 ES010758
6 · The paper itself

Abstract

backgroundPrevious studies showed that lifestyle behaviors (cigarette smoking, alcohol, coffee) are inversely associated with Parkinson's disease (PD). The prodromal phase of PD raises the possibility that these associations may be explained by reverse causation.

objectiveTo examine associations of lifestyle behaviors with PD using two-sample Mendelian randomisation (MR) and the potential for survival and incidence-prevalence biases.

methodsWe used summary statistics from publicly available studies to estimate the association of genetic polymorphisms with lifestyle behaviors, and from Courage-PD (7,369 cases, 7,018 controls; European ancestry) to estimate the association of these variants with PD. We used the inverse-variance weighted method to compute odds ratios (ORIVW) of PD and 95%confidence intervals (CI). Significance was determined using a Bonferroni-corrected significance threshold (p = 0.017).

resultsWe found a significant inverse association between smoking initiation and PD (ORIVW per 1-SD increase in the prevalence of ever smoking = 0.74, 95%CI = 0.60-0.93, p = 0.009) without significant directional pleiotropy. Associations in participants ≤67 years old and cases with disease duration ≤7 years were of a similar size. No significant associations were observed for alcohol and coffee drinking. In reverse MR, genetic liability toward PD was not associated with smoking or coffee drinking but was positively associated with alcohol drinking.

conclusionOur findings are in favor of an inverse association between smoking and PD that is not explained by reverse causation, confounding, and survival or incidence-prevalence biases. Genetic liability toward PD was positively associated with alcohol drinking. Conclusions on the association of alcohol and coffee drinking with PD are hampered by insufficient statistical power.

Indexed as

CoffeeParkinson DiseaseAgedAlcohol DrinkingGenome-Wide Association StudyHumansMendelian Randomization AnalysisRisk FactorsSmokingCoffeealcoholcoffeeMendelian randomisationParkinson’s diseaseSmoking

Identifiers

PMID34633332
PMCPMC9211765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.